MIAMI, Sept. 2, 2026 — H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $75 billion of capital under management, is pleased to announce that one of its affiliates has completed the acquisition of Outcomes One (“Outcomes” or the “Company”), a leading provider of clinical network services and pharmacy technology.

Headquartered in Orlando, Florida, Outcomes provides clinical network services and pharmacy technology solutions to pharmacies, health plans, pharmaceutical manufacturers, and data partners. Through its leading national network, which encompasses approximately 85% of U.S. pharmacies, the Company meaningfully improves patient health by enabling pharmacist-delivered clinical interventions and medication-based care. In 2025, the Company facilitated more than 10 million clinical interventions across 130 million covered lives. The Company additionally provides an integrated technology suite, including pharmacy management software and workflow automation solutions, to pharmacies nationwide, supporting critical daily operations such as prescription processing, dispensing, billing, and inventory management. Outcomes’ solutions span national and regional pharmacy chains, health systems, specialty and long-term care providers, and independent community pharmacies.

Jude Dieterman, Chief Executive Officer of Outcomes, noted, “Outcomes was built around the belief that pharmacists play a critical role in improving patient health. Our partnership with H.I.G. will provide additional resources and expertise to continue investing in our unique pharmacist-led clinical network, our leading technology platforms such as Rx30, Computer-Rx, and Outcomes Premium, and to deliver even greater value to pharmacies, health plans, pharmaceutical manufacturers, and patients.”

“Outcomes has built a unique technology platform that enables critical health services that are proven to improve patient outcomes,” commented Arjun Mohan, Managing Director at H.I.G. “We are excited to further that cause by partnering with the Outcomes team to support their commitment to deliver quality technology, services, and innovation to customers while elevating the role of pharmacies in the healthcare system.”

H.I.G. was advised by William Blair & Co. LLC and Kirkland & Ellis LLP. Outcomes was advised by TripleTree LLC and Simpson Thacher & Bartlett LLP.

About Outcomes

Outcomes is a leading provider of clinical network services and pharmacy technology that puts the pharmacy at the center of healthcare. Through its national network and integrated technology suite, the Company facilitates clinical interventions, improves medication adherence and patient health, streamlines pharmacy operations, and creates new economic opportunities for pharmacy partners. Outcomes’ solutions include its clinical platform, pharmacy management software, patient engagement and automation tools, and data and analytics. For more information, please visit outcomes.com.

About H.I.G. Capital

H.I.G. Capital is a leading global alternative investment firm with $75 billion of capital under management.* Based in Miami, and with offices in Atlanta, Boston, Chicago, Los Angeles, New York, San Francisco, and Stamford in the United States, as well as international affiliate offices in Hamburg, London, Luxembourg, Madrid, Milan, Paris, Bogotá, Rio de Janeiro, Dubai, and Hong Kong, H.I.G. specializes in providing both debt and equity capital to middle market companies, utilizing a flexible and operationally focused/value-added approach: 

• H.I.G.’s equity funds invest in management buyouts, recapitalizations, and corporate carve-outs of both profitable as well as underperforming manufacturing and service businesses.
• H.I.G.’s debt funds invest in senior, unitranche, and junior debt financing to companies across the size spectrum, both on a primary (direct origination) basis, as well as in the secondary markets.
• H.I.G.’s real estate funds invest in value-added properties, which can benefit from improved asset management practices.
• H.I.G. Infrastructure focuses on making value-add and core plus investments in the infrastructure sector.

Since its founding in 1993, H.I.G. has invested in and managed more than 400 companies worldwide. The Firm’s current portfolio includes more than 100 companies with combined sales in excess of $53 billion. For more information, please refer to the H.I.G. website at hig.com.

*Based on total capital raised by H.I.G. Capital and its affiliates.

Contact:

Arjun Mohan
Managing Director
[email protected]

Christopher Kozak
Principal
[email protected]

H.I.G. Capital
1450 Brickell Avenue
31st Floor
Miami, FL 33131
P: 305.379.2322
hig.com

SOURCE H.I.G. Capital

AUSTIN, Texas, Sept. 2, 2026 — Critical Materials Group (CMG), a privately owned U.S.-based manufacturing company modernizing domestic energetics production, today announced it has raised $10.3M in Seed funding led by Overmatch Ventures, with participation from Victory Six Advisors and Fulcrum Ventures. The round will be used to accelerate development and commissioning of CMG’s modular energetics production platform, expand the company’s engineering and operations team, and advance regulatory milestones.

The investment comes as demand for domestic munitions and advanced energetics production reaches a critical inflection point. Decades of consolidation have left U.S. energetics manufacturing concentrated in a small number of facilities with limited surge capacity, creating strategic vulnerabilities that have grown more acute amid sustained global conflict and accelerating allied demand. CMG is developing modular, automation-ready production platforms designed to expand and strengthen the existing industrial base, giving established manufacturers and defense primes the capacity, flexibility, and resilience needed to meet sustained production requirements without disrupting proven operations.

“The U.S. energetics industrial base, from the GOCOs to the prime contractors that depend on them, has been the backbone of American energetics for generations – CMG was built to add capacity to that ecosystem,” said Kevin Capozzoli, CEO and Co-Founder of Critical Materials Group.” This funding accelerates our ability to bring modular, automation-ready production online as a complementary source that gives the industrial base the flexibility and surge capacity it needs to meet a demand signal that isn’t slowing down.”

The Seed funding will also allow CMG to meet current commitments across its contract portfolio and move faster on facility commissioning as demand from U.S. government customers continues to build. The company is simultaneously building out its government relations and regulatory compliance infrastructure to support long-term production partnerships.

“CMG sits at the intersection of geopolitics and deep tech. Energetics, like rare earth minerals, sit upstream of nearly every U.S. kinetic capability, and recent conflicts have exposed the enormous gap between peacetime production and wartime consumption. But Kevin and Travis are ultimately why we led this round. Kevin is an uncommon combination of end-user and exceptional operator. He has seen firsthand what a thin industrial base costs downrange. Travis runs one of the few private labs in the country that can formulate, test, and qualify energetic materials. Together, they are the team to rebuild the arsenal we need to deter, and if necessary defeat, our adversaries,” said Morgan Hitzig, General Partner at Overmatch Ventures.

Founded in 2025, CMG has moved quickly to establish technical credibility and government alignment in a sector defined by long procurement cycles and high barriers to entry. The company’s founding team brings experience from military service, defense contracting, and procurement, positioning itself as a trusted partner capable of filling the arsenal gaps the modern threat environment demands.

About Critical Materials Group (CMG):
Founded in 2025, Critical Materials Group, Inc. (CMG) is a privately held, Texas-based manufacturing company modernizing energetics production facilities critical to national security. CMG delivers modular, automation-ready production platforms and integrated techniques that embed safety into every stage of the manufacturing process, enabling resilient, scalable, and responsible domestic energetics production. Led by industry experts from laboratory and operational backgrounds, CMG is committed to safely and responsibly enabling lethality at scale to support allied defense readiness.

Media Contact:
[email protected]

SOURCE Critical Materials Group

– Typewriter’s site-specific, non-viral technology uses only LNP-delivered RNA to insert whole genes into the genome, to create safer, re-dosable, durable genetic medicines –

– Matthew Stanton, PhD, and Leanne Peiser, DPhil, appointed CEO and CSO, respectively; former Pfizer CSO Mikael Dolsten, MD, PhD, joins Typewriter board as independent director and the Fred Hutch’s Stanley R. Riddell, MD, joins Typewriter Scientific Advisory Board –

CAMBRIDGE, Mass. and TOKYO, Sept. 2, 2026 — Typewriter Therapeutics, Inc., a biotech company developing safe, durable and re-dosable genetic medicines with curative impact for patients with cancer, autoimmune diseases, and severe genetic diseases, today emerged from stealth with $56 million in Series A financing led by AN Venture Partners and RA Capital Management with participation from ANRI, Gemseki, and SBI US Gateway Fund. In addition, Typewriter announced the appointments of Matthew Stanton, PhD, as Chief Executive Officer, Leanne Peiser, DPhil, as Chief Scientific Officer, and Mikael Dolsten, MD, PhD, as a member of the company’s board of directors.

Typewriter’s Target-Primed Reverse Transcription (TPRT) technology platform is built on the R2 retrotransposon, a natural gene-insertion system discovered by the company’s academic co-founders. Typewriter’s two-part, all-RNA therapy comprises a payload mRNA to make the R2 protein and a second RNA containing the therapeutic gene flanked by sequences to recruit the R2 protein. Inside the cell, the two assemble into an active complex that inserts the gene into the specific target site by TPRT. The R2 machinery then degrades along with the mRNA, leaving only the inserted gene at its intended location.

Typewriter’s initial focus will be on two high-value indications with life-changing potential to patients: in vivo CAR T and genetic liver diseases. The company’s first NHP studies are planned for late 2026.

“By inserting a durable, functioning gene into a safe-harbor site in T cells using lipid nanoparticle-delivered RNA, our technology is designed to create safer, re-dosable genetic medicines that are accessible to many more patients than current cumbersome and complex CAR T approaches,” said Matthew Stanton, PhD, Chief Executive Officer and Board Director of Typewriter Therapeutics. “This financing enables us to build on the proof-of-concept we have established in humanized mouse models and establish our first in vivo CAR T development candidate.”

Prior to Typewriter, Matthew Stanton was a Venture Partner at Raven, RA Capital’s healthcare incubator. Before Raven, he spent seven years at Generation Bio, first as Chief Technology Officer and for the past five years as Chief Scientific Officer. Prior to Generation, he was Vice President and Head of Chemistry at Moderna Therapeutics, where his team identified proprietary lipid nanoparticles for vaccine development and helped to bring the first mRNA vaccines into clinical development.

Newly appointed CSO Leanne Peiser brings to Typewriter more than 20 years of R&D leadership across biotech and pharma, with deep expertise in immunology, immunotherapy, and cellular therapy, including autologous, allogeneic, and in vivo CAR T for oncology and autoimmune diseases. Most recently, as Executive Director of Translational Research, Cellular Therapy at Bristol Myers Squibb (BMS), she served as a senior scientific lead for their CAR T portfolio across multiple indications.

“The mRNA vaccines proved to the world that RNA delivered by a lipid nanoparticle can become a medicine at global scale. Typewriter takes that breakthrough a decisive step further –using only RNA not to express a transient protein, but to write a durable therapeutic gene into a precise, safe location in the genome, without a virus,” said Mikael Dolsten, MD, PhD, independent board director at Typewriter Therapeutics and former Chief Scientific Officer and President of Worldwide Research & Development at Pfizer. “I am especially excited by what this means for in vivo CAR T. Engineering a patient’s own T cells in vivo with an LNP-delivered RNA medicine could combine simpler administration with durable CAR expression and the ability to re-dose, potentially making cell therapy safer and accessible to far more patients than today’s complex manufacturing allows. It is a privilege to join the board and help bring this platform to patients with cancer, autoimmune, and genetic diseases.”

Typewriter is led by an experienced management team, including:

• Matthew Stanton, PhD, Chief Executive Officer
• Leanne Peiser, DPhil, Chief Scientific Officer
• Jun Zhou, PhD, Founder and Vice President, Discovery and Global Operations
• Ari Friedland, PhD, Vice President, Research
• Mayu Yoshikawa, PhD, President, Typewriter Japan

In addition to Matthew Stanton and Mikael Dolsten, Typewriter’s board of directors includes board chair Ken Horne, Managing Partner, AN Venture Partners and Laura Tadvalkar, PhD, Managing Director at RA Capital.

Typewriter also announced that Stanley R. Riddell, MD, has joined as a member of its Scientific Advisory Board. Dr. Riddell is a member of the Translational Science and Therapeutics Division at Fred Hutchinson Cancer Center and Professor of Medicine at the University of Washington. He was the principal investigator on the first human trial of adoptively transferred therapeutic T cells, and his laboratory’s CAR T work was licensed to Juno Therapeutics, which he co-founded and which is now part of Bristol Myers Squibb.

About Typewriter Therapeutics

Typewriter Therapeutics is a start-up company that focuses on developing and commercializing RNA-based gene therapies for patients suffering from cancer, autoimmune, and severe genetic disorders. Typewriter’s cutting-edge platform technology enables the targeted insertion of whole therapeutic genes to create safer, durable, and re-dosable medicines. Founded in February 2022, the company builds on the research of Professor Emeritus Haruhiko Fujiwara of the University of Tokyo on transposons. With research facilities in Tokyo and Cambridge, USA, Typewriter is committed to bringing Japan-originated technology to the global stage. For more information, visit www.typewritertx.com.

SOURCE Typewriter Therapeutics, Inc.

• IBM Ventures has invested in BQP, bringing total funding to $8M and backing BQP’s expansion from engineering design into real-time operational decisions. The investment extends a technical relationship that began in 2023, when BQP joined the IBM Quantum Network.
• Classical solvers leave roughly 85% of a GPU’s floating-point capacity idle. BQP’s flagship platform, BQPhy®, puts that capacity to work, resolving full-fidelity physics inside operational decision windows.
• BQPhy® is in production with aerospace and defense customers, with contracted and committed revenue up 8x since BQP’s 2025 seed round and 3x customer growth.

SYRACUSE, N.Y., Sept. 2, 2026 — BQP, the physics acceleration company, today announced a strategic investment from IBM Ventures, the venture capital arm of IBM. The investment brings BQP’s total funding to $8M and funds BQPhy®’s expansion from engineering design into operational deployment, scaling delivery and go-to-market as BQP expands beyond aerospace and defense. Venn10 Capital and existing investor Monta Vista Capital also participated. Since its 2025 seed round, backed by New York State’s venture arm and other institutional investors, BQP has grown contracted and committed revenue 8x, tripling its customer base and growing platform users 20x.

“An engineer with a deadline doesn’t care where the answer came from. They care that it arrived in time and that the physics is right. The industry spent years treating this as a hardware problem that warranted faster chips, more of them, and eventually a quantum one. But it was always a software problem,” said Abhishek Chopra, Founder and CEO of BQP.

Chopra added: “We spent those years earning our way into engineering workflows, so when the quantum machines are ready, nothing about how those teams work has to change. That’s the path IBM has watched us build since 2023, and this investment says it’s the right one.”

Mission-critical decisions have deadlines, and high-fidelity physics simulations rarely meet them. More hardware has not closed the gap. Classical physics solvers leave roughly 85% of a GPU’s floating-point capacity idle, because the sparse iterative methods underneath simulation are bound by memory access rather than compute. Teams choose between accurate models that return the right answer too late, or fast methods that answer on time by skipping the physics, leaving hidden risk behind over-engineered safety margins.

BQPhy® removes this trade-off between speed and accuracy. Its physics-AI optimization engine resolves the full physics inside the decision window, using the GPU capacity classical solvers leave idle. The platform delivers this through two solvers that share a single SDK, integrated natively into MATLAB as a MathWorks Connections Program partner, with standard APIs for Python, Julia, and other frameworks. This enables engineers to get the answers without leaving the tools they already use. QuantumNOW™ is in production today on customers’ existing CPU and GPU infrastructure, and each deployment maps which problems belong on a QPU – making QuantumMAX™, BQP’s quantum-native solver in development, an on-ramp rather than a bet. It is written for heterogeneous CPU-GPU-QPU execution rather than a single hardware target.

“What stood out with BQP is that users don’t have to change how they work to get quantum-accelerated results. Their proven track record of developing software that helps enterprises build a practical path toward hybrid quantum-classical computing is what gives IBM Ventures confidence in making this investment,” said Emily Fontaine, Global Head of IBM Ventures.

In aerospace and defense, BQP’s furthest-along work is in space. Under an SBIR with the U.S. Space Force and SpaceWERX, extending earlier work with the SDA TAP Lab, BQPhy®’s physics AI propagates a catalog of more than 3,000 space objects in under a second, roughly 250x faster than the open-source Orekit solver by compressing the model using proprietary algorithms.BQP also holds a CRADA with the Air Force Research Laboratory’s Aerospace Systems Directorate and has demonstrated BQPhy® on radio-frequency signal problems for the tactical edge with NavalX. With Modovolo, BQP built a system-level propulsion optimization for UAV mission profiles, expanding from three design variables to more than twelve and tuning propeller and motor as a single unit; integration took roughly one week through the API.

In energy, BQP is applying the same platform to commercial systems, with EV battery thermal management work funded by India’s Ministry of Heavy Industries and the Indian School of Business.

The same engine that predicts where a satellite is heading also predicts how heat moves through a battery pack or a data center rack: different industries with the same high-dimensional physics that has to resolve before the decision window closes.

QuantumNOW™ is in production; QuantumMAX™ is proving out. In work presented at USNC/TAM 2026, BQP ran QuantumMAX™ on quantum hardware for uncertainty quantification in computational fluid dynamics, reaching the same accuracy as classical Monte Carlo with fewer samples on a benchmark-scale problem. BQP’s research is published in IEEE, AIAA, and APL Quantum, with best paper awards at AeroCon 2026 and the IEEE Space, Aerospace and Defence Conference (SPACE 2026).

Media Contact
Ludington Media on behalf of BQP
[email protected]
New York, NY • (551) 795-5950

About BQP

BQP (formerly BosonQ Psi) is a physics acceleration company applying quantum algorithms to mission-critical operational decisions. Its unified Quantum-HPC platform, BQPhy®, pairs physics AI surrogates with an optimization solver, delivering results on today’s CPU and GPU infrastructure through QuantumNOW™ with quantum-native acceleration in development through QuantumMAX™ – both on a single SDK. Headquartered in Syracuse, New York, with offices in the UK and India. Learn more at https://www.bqpsim.com

SOURCE BQP

Partnering with Investors and Validators for Social Good

PIERRE, S.D., Sept. 2, 2026 — Aegis Trust, a SEC qualified custodian for digital assets, today announced the development of the world’s first tokenized money market fund that focuses on social impact. Leveraging the blockchain eliminates delays, reduces inefficiencies, and restores trust in global aid systems. Aegis Trust is working with global investors and partners to demonstrate how investment returns and tokenized capital can help fund disaster response and humanitarian relief.

Through a partnership with regulated asset manager, the Tokenization Foundation Money Market Fund is designed to optimize cash management while generating measurable global impact through tokenized aid. Aegis Trust pledges to donate 10% of gross revenue received from this Money Market Fund to humanitarian aid and disaster relief, and benefits investors, aid workers and council members with TF Tokenized Coins.  Investors are also allocated 10% TF Coins up to the first US$10B AUM. Nonprofit organization including aid workers can receive 10% TF Coins from AI-enabled activations and as they accrue TF Coins. As Super Validators, with governing rights to the infrastructure and information rights of the rail including reporting, monitoring, 10% TF Coin are allocated to 10 Council Members.

“The future of financial services is going digital and as the need for blockchain and digital asset financial solutions grows, Aegis Trust is working with global council members to build Tokenization Foundation on crisis capital infrastructure where the blockchain enables instant, traceable, and secure transfers for humanitarian aid,” said Serra Wei, Cofounder of Aegis Trust and the Tokenization Foundation. “The Tokenization Foundation looks to relieve aid trapped in slow grant cycles, burdened by administrative overhead, and limited by opaque reporting systems to deliver funding instantly, transparently, and at scale.”

In addition to Aegis Trust, the Digital Chamber has agreed to become a founding council member. “As the world’s oldest and largest digital assets trade association, we support Aegis Trust’s efforts and are excited to see how the Tokenization Foundation begins to give back and grow broader investment education and social good,” said Anastasia Dellacio, Executive Director of The Digital Chamber’s State Network. “This initiative supports our mission to a fair and inclusive financial ecosystem where everyone has the opportunity to participate.”

Aegis Trust is adding banking expert Steve Andrews as a member of the Board of Director at Aegis Trust to support governance and risk management with current board members Lynne Marlor, Dave Timpe and Todd Bernard. Steve’s long career involved the operational aspects of running five banks as the President and CEO.

About Aegis Trust:

Aegis Trust (https://www.aegiscustody.com), a SEC qualified custodian for blockchain transactions, provides high-quality, secure, institutional-grade, proprietary, integrated custody solutions. Aegis Trust is a blockchain company with offices in the US and utilizes its South Dakota Trust Charter to hold all digital assets in segregated and transparent custody accounts. With an experienced executive team and global partners across traditional and digital financial services, Aegis Trust is building a tokenized ecosystem with impact.

About The Digital Chamber:

The Digital Chamber is a non-profit organization committed to promoting global blockchain adoption. We envision a fair and inclusive digital and financial ecosystem where everyone has the opportunity to participate. Access to digital assets is not merely a technological advancement but a fundamental human right, crucial for economic and social empowerment. Through targeted education, advocacy, and strategic collaborations with government and industry stakeholders, we drive innovation and shape policies that create a favorable environment for the blockchain technology ecosystem.

The Digital Chamber’s umbrella includes: CryptoUK, Digital Power Network (DPN), TDC’s Digital State Network, and Treasury Council.

Media Contact:

Jan Jahosky

[email protected] 

407.331.4699

SOURCE The Tokenization Foundation

The identity engine now reasons across users, sessions, and attack sequences — including the login that already succeeded

BREA, Calif., Sept. 2, 2026 — ThreatHunter.ai, a Service-Disabled Veteran-Owned Small Business, today released MILBERT 2.1 for hybrid Active Directory and Entra ID. Version 2.1 adds continuous user-behavior tracking and is built to catch identity attacks that start after a successful login: adversary-in-the-middle phishing, session theft, and token replay.

MILBERT 2.1 does not treat a completed MFA challenge as proof of a legitimate user. It scores the principal, the session, and the sequence around both.

Two models, one decision

A gradient-boosted model scores each authentication event. A fine-tuned language model reads a window of events for a user or session. The language model may label an attack chain, write a short rationale, and recommend Allow, Monitor, Investigate, or Block. It does not revoke sessions or change directory state. Session kill, token revocation, and related actions stay with policy and with hunt analysts when the customer is on ARGOS.

Training used production authentication telemetry, MFA session-theft cases, and live user-behavior observations. Raw corpus counts are not being published.

What 2.1 detects

AiTM phishing and proxy MFA bypass after a valid login; stolen cookies, refresh-token abuse, and sessions replayed from attacker infrastructure; device, network, or timing that does not match the user’s baseline; backdoor accounts and service-account abuse; hybrid on-premises-to-cloud pivots; and privilege use that diverges from established behavior.

“Attackers do not break in. They log in,” said James McMurry, founder and CEO of ThreatHunter.ai. “Every incident we have worked this year started with a valid credential. MFA does not catch it when the attacker steals the session after the user finishes the prompt. Version 2.1 watches the person behind the credential, and the session after the login.”

In March 2026 the company published the first public documentation of an Iranian operational server used to pre-position against Stryker Corporation, five days before the March 11 wipe. The identity lesson is the same: the compromise often looks legitimate until the sequence is reconstructed.

A single MILBERT 2.1 instance scores more than 74,000 authentication events per second at 99.94 percent ROC-AUC on infrastructure ThreatHunter.ai owns and operates. That path is required for CMMC and FERPA customers who cannot send identity telemetry to public-cloud AI services. MILBERT is an analysis layer. It does not replace the identity provider, MFA, or Conditional Access.

MILBERT 2.1 is available now at threathunter.ai/milbert.

About ThreatHunter.ai

ThreatHunter.ai is a Service-Disabled Veteran-Owned Small Business in Brea, California, with offices in Washington, D.C., and Las Vegas. An MSSP Alert Top 50 firm, it provides managed threat hunting and identity detection to defense contractors, higher education, and commercial enterprises. CEO James McMurry is a U.S. Coast Guard veteran and co-founder of VETCON. threathunter.ai

Media contact

ThreatHunter.ai Press Desk • [email protected] • +1 888 674 9001 • [email protected]

SOURCE ThreatHunter.ai

New funding will accelerate Capacity’s next phase as enterprises consolidate AI investments around fewer, more strategic platforms

ST. LOUIS, Sept. 2, 2026 — Capacity, the agentic support automation platform, today announced more than $54M in Series E funding, bringing its total amount raised to date to over $159M. The round follows years of rapid expansion for Capacity, which surpassed $100 million in annual recurring revenue (ARR) in June, growing 20x in 3.5 years.

“We invest in people and companies that have a clear sense of purpose and the ability to execute on it,” said Kathy Ireland, a lead investor of the round. “Capacity has demonstrated both over the past year we’ve worked with them. I’ve seen firsthand the value the technology delivers, and it’s clear there is a significant opportunity ahead for Capacity.”

The investment comes as enterprises become more selective about where they spend their AI budgets. After years of experimentation with multiple point solutions, organizations are looking to consolidate their tech stacks into a platform that supports AI across the entire business and delivers measurable ROI. Capacity has been building towards this shift through continued product development, partnerships and strategic acquisitions.

“A few years ago at Capacity, we made a bet that companies would want fewer vendors,” said David Karandish, CEO and founder of Capacity. “The success of that bet is evident as we continue to grow. As enterprise AI use cases increase, so can complexities. Companies need a way to expand what AI can do without having to rebuild each time. Our train once, use everywhere approach means they can power every channel from the same foundation rather than managing a collection of standalone capabilities.”

Investing in Capacity’s Future

Capacity brings traditionally separate customer experience capabilities together through a shared platform and knowledge orchestration layer. The approach is designed to reduce the integration work required to deploy, manage and expand AI across customer support operations.

The new investment will help the company continue to build in areas such as:

Product

• Accelerate research and development across the Capacity platform, with continued investment in AI agents, automation and enterprise knowledge orchestration.
• Continue advancing AI solutions that improve operational efficiency and customer experiences.

Customers

• Expand go-to-market and customer success teams to support continued customer growth and adoption.

Scale

• Invest in strategic partnerships and platform integrations to expand Capacity’s ecosystem.
• Support continued international expansion as Capacity increases its global footprint.

In addition to the raise and its ARR milestone, Capacity also recently ranked in the top 10% of the 2026 Inc. 5000, placing it among the 500 fastest-growing private companies in the U.S. The capital will build on this momentum by deepening Capacity’s presence in key industries and continuing its global expansion.

To learn more about Capacity, visit: Capacity.com

About Capacity

Founded in 2017, Capacity is the agentic support automation platform that powers every customer experience activity from a single AI knowledge orchestration layer. Capacity unifies omnichannel AI agents, real-time agent assist, automated quality assurance, conversational intelligence and proactive outbound WhatsApp, SMS and voice campaigns into a single platform so organizations can deliver faster, more consistent support. More than 20,000 organizations rely on Capacity to deflect repetitive inquiries, empower human agents, automate post-interaction work and proactively engage customers. To learn more about Capacity, visit Capacity.com.

Media Contact
PANBlast for Capacity
[email protected]

SOURCE Capacity

Die Runde wurde von Neurimmune und Pureos angeführt, unter Beteiligung bestehender und neuer Investoren; ergänzt wurde sie durch eine nicht verwässernde Finanzierung durch die Schweizer Paraplegiker-Stiftung und die Wings for Life – Spinal Cord Research Foundation.

SCHLIEREN, Schweiz, 2. September 2026 — Die NovaGo Therapeutics AG, ein Biotechnologieunternehmen im klinischen Stadium, das Anti-Nogo-A-Biologika für Erkrankungen des Zentralnervensystems entwickelt, gab heute den erfolgreichen Abschluss einer Serie-B-Finanzierungsrunde in Höhe von 24 Millionen CHF (30 Millionen US-Dollar) bekannt. Die Runde wurde von Neurimmune und Pureos angeführt, unter Beteiligung bestehender und neuer Investoren. Die Eigenkapitalfinanzierung wird durch eine nicht verwässernde Finanzierung seitens der Schweizer Paraplegiker-Stiftung und von Wings for Life ergänzt.

Die Mittel aus der Finanzierung werden dazu verwendet, das Leitprogramm von NovaGo in eine Proof-of-Concept-Studie (PoC) bei Patienten mit akuter Rückenmarksverletzung voranzutreiben. Bei der Studie handelt es sich um eine vollständig randomisierte Doppelblindstudie, an der 120 Patienten an Standorten in Deutschland, Spanien und der Schweiz teilnehmen.

Rückenmarksverletzungen stellen nach wie vor einen Bereich mit hohem ungedecktem medizinischem Bedarf dar. Derzeit gibt es keine zugelassenen regenerativen Behandlungsmöglichkeiten, die verlorene neurologische Funktionen wiederherstellen, sodass Patienten und ihre Familien nach einer Verletzung nur begrenzte therapeutische Perspektiven haben. Der Ansatz von NovaGo zielt auf Nogo-A ab, ein Protein, das die Regeneration von Nervenfasern und die Neuroplastizität im zentralen Nervensystem hemmt, mit dem Ziel, eine funktionelle Erholung zu ermöglichen.

„Wir freuen uns sehr, dass dieses Programm nun in diese entscheidende Phase der klinischen Erprobung vorrückt und uns damit einem dringend benötigten Behandlungsansatz für Patienten, die mit den Folgen einer Rückenmarksverletzung leben, einen bedeutenden Schritt näher bringt”, sagte Prof. Martin Schwab, Chief Scientific Officer von NovaGo Therapeutics.

„Gemeinsam mit NovaGo Therapeutics erschließen wir einen neuartigen Ansatz zur Behandlung von Rückenmarksverletzungen unter Verwendung eines vollständig humanen therapeutischen Antikörpers, der das Nervenwachstum nach einer Verletzung fördern soll”, sagte Prof. Roger M. Nitsch, Präsident und Vorstandsvorsitzender von Neurimmune sowie Mitglied des Vorstands von NovaGo Therapeutics. „Wir sind von den vielversprechenden Phase-1-Ergebnissen mit NG004 sehr ermutigt und freuen uns darauf, das klinische Entwicklungsprogramm gemeinsam mit NovaGo Therapeutics und unseren Co-Investoren sowie mit großzügiger Unterstützung der Schweizer Paraplegiker-Stiftung und von Wings for Life voranzutreiben.”.

„Wir freuen uns sehr, diese Finanzierungsrunde mit zu leiten und die nächste Entwicklungsphase von NovaGo zu unterstützen. Die Fortschritte und Ergebnisse der Phase-1-Studie bei Rückenmarksverletzungen sind sehr ermutigend, und wir sehen großes Potenzial darin, eine neue regenerative Behandlungsoption für Patienten mit Rückenmarksverletzungen bereitzustellen”, sagte Dominik Escher, geschäftsführender Gesellschafter bei Pureos Bioventures.

„Wir sind zutiefst dankbar für die Unterstützung unserer Investoren. Auch die Unterstützung durch Wings for Life und die Schweizer Paraplegiker-Stiftung war entscheidend und hat dazu beigetragen, diese wichtige Entwicklungsphase zu ermöglichen”, sagte Stefan Moese, Chief Executive Officer von NovaGo Therapeutics. „Ihr Engagement ermöglicht es uns, die Proof-of-Concept-Studie voranzutreiben und darauf hinzuarbeiten, Patienten, die unter den verheerenden Folgen einer Rückenmarksverletzung leiden, eine dringend benötigte Behandlung zur Verfügung zu stellen.”

Informationen zu Pureos Bioventures

Pureos Bioventures ist ein Venture-Fonds, der von der Schweizer Risikokapitalgesellschaft Pureos Partners beraten wird. Er investiert ausschließlich in private, innovative Arzneimittelentwicklungsunternehmen, wobei ein besonderer Schwerpunkt auf der nächsten Generation biologischer Arzneimittel und Darreichungsformen liegt. Die Portfoliounternehmen des Fonds stützen sich auf wissenschaftliche Exzellenz, um Therapien für ein breites Spektrum an Indikationen zu entwickeln, darunter Onkologie, Immunologie, Augenheilkunde, seltene Krankheiten und Neurowissenschaften. Pureos hat ein Team mit fundierter Expertise in den Bereichen Investment, Betriebsführung und Klinik aufgebaut, das bestrebt ist, das Leben von Patienten positiv zu beeinflussen, indem es innovative Therapien für verheerende Krankheiten vorantreibt. Weitere Informationen finden Sie unter www.pureosbio.com.

Informationen zu Neurimmune

Neurimmune ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das Antikörpertherapeutika der nächsten Generation entwickelt. Das Unternehmen leistet Pionierarbeit auf dem Gebiet der Amyloid-Depletion als neuartigem therapeutischen Mechanismus zur Behandlung von Erkrankungen des Zentralnervensystems und damit verbundenen Proteinklumpungserkrankungen, darunter Alzheimer, amyotrophe Lateralsklerose und ATTR-Kardiomyopathie. Neurimmune hat den Anti-ATTR-Antikörper Cliramitug (früher NI006, ALXN2220, Phase 3) für die ATTR-Kardiomyopathie, den Anti-falschgefalteten-SOD1-Antikörper AP-101 (Phase 2) für ALS, den Anti-Nogo-A-Antikörper NG004 (Phase 1) für Rückenmarksverletzungen sowie den Anti-Amyloid-Leichtketten-Antikörper NI009 (präklinisch) für die AL-Amyloidose entdeckt.

Informationen zu NovaGo Therapeutics

Die NovaGo Therapeutics AG ist ein Biotechnologieunternehmen im klinischen Stadium, das neuartige Anti-Nogo-A-Biologika entwickelt, um die Nervenregeneration und die funktionelle Erholung bei Patienten mit Erkrankungen und Verletzungen des Zentralnervensystems, einschließlich Rückenmarksverletzungen, Schlaganfall und sekundär progredienter Multipler Sklerose, zu fördern. Aufbauend auf bahnbrechenden Forschungsergebnissen zu Nogo-A als einem zentralen Hemmfaktor der neuronalen Regeneration treibt NovaGo die klinische Entwicklung seines Leitkandidaten voran, mit dem Ziel, die erste regenerative Therapie für Patienten mit akuter Rückenmarksverletzung auf den Markt zu bringen. NovaGo hat seinen Sitz in der Schweiz.

Für weitere Informationen wenden Sie sich bitte an:

NovaGo Therapeutics AG
[email protected]
www.novagotherapeutics.com 

Round led by Neurimmune and Pureos, with participation from existing and new investors; complemented by non-dilutive funding from the Swiss Paraplegic Foundation and Wings for Life – Spinal Cord Research Foundation.

SCHLIEREN, Switzerland, Sept. 2, 2026 — NovaGo Therapeutics AG, a clinical-stage biotechnology company developing anti-Nogo-A biologics for diseases of the central nervous system, today announced the successful completion of a CHF 24 million (USD 30 million) Series B financing round. The round was led by Neurimmune and Pureos, with participation from existing and new investors. The equity financing is complemented by non-dilutive funding from the Swiss Paraplegic Foundation and Wings for Life.

Proceeds from the financing will be used to advance NovaGo’s lead program into a proof-of-concept (PoC) study in patients with acute spinal cord injury. The study is a fully randomized, double-blind trial enrolling 120 patients across sites in Germany, Spain, and Switzerland.

Spinal cord injury remains an area of high unmet medical need. There are currently no approved regenerative treatment options that restore lost neurological function, leaving patients and their families with limited therapeutic prospects following injury. NovaGo’s approach targets Nogo-A, a protein that inhibits nerve fiber regeneration and neuroplasticity in the central nervous system, with the goal of enabling functional recovery.

“We are excited to see this program progress into this critical stage of clinical testing, bringing us a meaningful step closer to a much-needed treatment for patients living with the consequences of spinal cord injury,” said Prof. Martin Schwab, Chief Scientific Officer of NovaGo Therapeutics.

“Together with NovaGo Therapeutics, we are pioneering a novel approach for the treatment of spinal cord injury using a fully human therapeutic antibody designed to promote nerve outgrowth after injury,” said Prof. Roger M. Nitsch, President and Chief Executive Officer of Neurimmune and a member of the Board of Directors of NovaGo Therapeutics. “We are encouraged by the promising Phase 1 results with NG004 and look forward to advancing the clinical development program together with NovaGo Therapeutics and our co-investors, with generous support from the Swiss Paraplegic Foundation and Wings for Life.”

“We are very pleased to co-lead this financing and support NovaGo’s next stage of development. The progress and results from the Phase 1 study in spinal cord injury are very encouraging and we see great potential to provide a new regenerative treatment option for patients with spinal cord injury,” said Dominik Escher, Managing Partner at Pureos Bioventures.

“We are deeply grateful for the backing of our investors. Support from Wings for Life and the Swiss Paraplegic Foundation have also been instrumental, helping make this crucial development phase possible.” said Stefan Moese, Chief Executive Officer of NovaGo Therapeutics. “Their commitment allows us to move forward with the proof-of-concept study and work toward bringing a much-needed treatment to patients affected by the devastating consequences of spinal cord injury.”

About Pureos Bioventures

Pureos Bioventures is a venture fund advised by the Swiss venture capital firm Pureos Partners. It invests exclusively in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. The fund’s portfolio companies are built on scientific excellence to develop therapies across a broad indication spectrum including oncology, immunology, ophthalmology, rare diseases, and neuroscience. Pureos has built a team with in-depth investment, operating and clinical expertise, that strives to impact patients’ lives by advancing innovative treatments for devastating diseases. For more information, please visit www.pureosbio.com.

About Neurimmune

Neurimmune is a clinical-stage biopharmaceutical company building next-generation antibody therapeutics. The company pioneers amyloid depletion as a novel therapeutic mechanism to treat CNS and related protein aggregation diseases including Alzheimer’s disease, amyotrophic lateral sclerosis and ATTR cardiomyopathy. Neurimmune discovered the anti-ATTR antibody cliramitug (formerly NI006, ALXN2220, Phase 3) for ATTR cardiomyopathy, the anti-misfolded SOD1 antibody AP-101 (Phase 2) for ALS, the anti-Nogo-A antibody NG004 (Phase 1) for spinal cord injury, and the anti-amyloid light chain antibody NI009 (preclinical) for AL amyloidosis.

About NovaGo Therapeutics

NovaGo Therapeutics AG is a clinical-stage biotechnology company developing novel anti-Nogo-A biologics to promote nerve regeneration and functional recovery in patients with diseases and injuries of the central nervous system, including spinal cord injury, stroke, and secondary progressive multiple sclerosis. Founded on pioneering research into Nogo-A as a key inhibitor of neuronal regeneration, NovaGo is advancing its lead candidate through clinical development with the goal of delivering the first regenerative treatment for patients with acute spinal cord injury. NovaGo is based in Switzerland.

For more information, please contact:

NovaGo Therapeutics AG
[email protected]
www.novagotherapeutics.com 

SOURCE NovaGo Therapeutics